Thermo Fisher Expects 7% Annual Organic Revenue Growth Over Long Term

Dow Jones
05/20
 

By Nicholas G. Miller

 

Thermo Fisher Scientific expects to record 7% annual organic revenue growth and low-teens adjusted-earnings-per-share growth over the long term.

The company, which is hosting its investor day Wednesday, said its market has improving demand trends and strong long-term growth fundamentals.

It also said AI will be a long-term driver of growth by accelerating scientific breakthroughs and improving returns on drug discovery, thereby fueling additional investment into Thermo Fisher customers' drug pipelines.

 

Write to Nicholas G. Miller at nicholas.miller@wsj.com

 

(END) Dow Jones Newswires

May 20, 2026 08:50 ET (12:50 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10